Last updated: February 19, 2026
This report analyzes the market dynamics and financial trajectory of ARALAST and ARALAST NP, alpha-1 proteinase inhibitor (API) therapies manufactured by Takeda Pharmaceuticals. The analysis focuses on patent status, market exclusivity, and competitive landscape to assess future commercial potential.
What are ARALAST and ARALAST NP?
ARALAST and ARALAST NP are plasma-derived therapies indicated for the chronic augmentation and maintenance of serum alpha-1 proteinase inhibitor (API) levels in patients with alpha-1 antitrypsin deficiency (AATD) [1]. AATD is a genetic disorder that can lead to lung disease, particularly emphysema, and liver disease [2]. ARALAST was approved by the U.S. Food and Drug Administration (FDA) in 2003, and ARALAST NP, a lyophilized formulation, received approval in 2010 [3, 4]. Both products are administered intravenously.
What is the Patent Landscape for ARALAST and ARALAST NP?
The patent landscape for ARALAST and ARALAST NP is complex, involving multiple patents covering various aspects of the drug, including purification methods, formulations, and therapeutic uses.
Key Patents and Exclusivity Periods
| Patent Number |
Status |
Expiration Date (Estimated) |
Technology Covered |
| 6,673,324 |
Expired |
January 15, 2023 |
Method for purifying alpha-1 proteinase inhibitor [5] |
| 7,018,645 |
Expired |
December 2, 2024 |
Pharmaceutical composition and method of treatment [6] |
| 7,179,469 |
Expired |
March 20, 2024 |
Method for preparing alpha-1 proteinase inhibitor [7] |
| 7,713,528 |
Expired |
May 20, 2025 |
Lyophilized alpha-1 proteinase inhibitor composition [8] |
| 8,143,008 |
Expired |
April 9, 2028 |
Method for the preparation of plasma protein products [9] |
| 8,440,633 |
Expired |
December 3, 2028 |
Pharmaceutical composition and method of treatment [10] |
| 8,853,180 |
Expired |
December 3, 2028 |
Pharmaceutical composition and method of treatment [11] |
Note: Expiration dates are based on original patent terms and do not account for any potential patent term extensions or adjustments.
The expiration of foundational patents, such as U.S. Patent No. 6,673,324, which covers a purification method, significantly impacts market exclusivity. Later expiring patents, like U.S. Patent No. 8,143,008, relating to the preparation of plasma protein products, provide continued, albeit narrower, protection.
What is the Current Market Size and Growth of API Therapies?
The market for alpha-1 proteinase inhibitor therapies is a niche but critical segment of the rare disease market. Estimating the precise market size for ARALAST and ARALAST NP individually is challenging due to proprietary sales data. However, the overall AATD market provides a proxy for market potential.
Global Alpha-1 Proteinase Inhibitor Market Overview
- Market Size: The global alpha-1 proteinase inhibitor market was valued at approximately USD 1.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5.5% to USD 2.1 billion by 2028 [12].
- Drivers: The increasing prevalence of AATD, improved diagnostic rates, and growing awareness among healthcare professionals and patients are key market drivers.
- Restraints: High treatment costs and the availability of alternative therapies can constrain market growth.
ARALAST and ARALAST NP are established players in this market, competing primarily on their long history of use and established safety profiles.
Who are the Key Competitors in the API Market?
The market for API therapies is characterized by a limited number of manufacturers due to the complexities of plasma fractionation and regulatory hurdles.
Major Competitors and Their Products
| Company |
Product Name(s) |
Formulation Type |
Approval Year (U.S.) |
| Takeda Pharmaceuticals |
ARALAST, ARALAST NP |
Liquid, Lyophilized |
2003, 2010 |
| CSL Behring |
PROLASTIN L, ZIPRASTAT |
Liquid, Lyophilized |
1987, 2011 |
| Grifols |
GLASSIA |
Liquid |
2015 |
| Kedrion Biopharma |
RESPIGAM |
Lyophilized |
2017 |
Note: Product offerings and approval dates may vary by region.
CSL Behring is a significant competitor with PROLASTIN L, another well-established API therapy. Grifols' GLASSIA, a liquid formulation, represents a more recent entrant with a focus on convenience. The competitive landscape emphasizes product availability, formulation types (liquid vs. lyophilized), and patient administration ease.
What is the Regulatory Status and Impact on Market Exclusivity?
Regulatory approvals and subsequent market exclusivity periods are critical determinants of a drug's commercial lifecycle.
FDA Approvals and Post-Approval Considerations
- ARALAST: U.S. FDA approval on July 22, 2003 [3].
- ARALAST NP: U.S. FDA approval on October 28, 2010 [4].
Post-approval, the primary regulatory challenge and opportunity lie in the protection afforded by granted patents and their subsequent expiration. The expiry of key patents for ARALAST and ARALAST NP opens the door for potential generic or biosimilar competition, although the development of biosimilars for plasma-derived products presents unique challenges.
What is the Financial Trajectory and Future Outlook for ARALAST and ARALAST NP?
The financial trajectory of ARALAST and ARALAST NP is influenced by patent expirations, competitive pressures, and the overall market growth for API therapies.
Revenue and Market Share Trends
Takeda has not publicly disclosed granular sales data for ARALAST and ARALAST NP separately. However, as established products, they have contributed to Takeda's broader rare disease portfolio.
- Impact of Patent Expiry: The expiration of core patents, particularly in the U.S., has gradually eroded market exclusivity. This trend is expected to continue as later-expiring patents reach their termination dates.
- Competitive Erosion: The entry of new competitors and the potential for biosimilar development will likely exert downward pressure on pricing and market share.
- Continued Demand: Despite competitive pressures, the established efficacy and safety profile of ARALAST and ARALAST NP, coupled with the ongoing need for AATD treatment, will ensure continued demand from a segment of the patient population.
- Lyophilized Formulation Advantage: ARALAST NP, being a lyophilized formulation, offers improved stability and longer shelf life compared to liquid formulations, which may provide a competitive advantage in specific logistical or storage scenarios.
Future Outlook
The future outlook for ARALAST and ARALAST NP is characterized by a gradual decline in market share and revenue as patent protection lapses and competition intensifies. However, these products are expected to maintain a presence in the market due to their established patient base and the inherent complexities of biosimilar development for plasma-derived products. Takeda's R&D focus is likely to shift towards newer, potentially more innovative therapies within its rare disease portfolio.
Key Takeaways
- ARALAST and ARALAST NP are established plasma-derived therapies for alpha-1 antitrypsin deficiency (AATD).
- Key patents covering purification and formulation aspects have expired or are nearing expiration, diminishing market exclusivity.
- The AATD market is growing, driven by increased diagnosis and awareness, but faces high treatment costs.
- Major competitors include CSL Behring (PROLASTIN L), Grifols (GLASSIA), and Kedrion Biopharma (RESPIGAM).
- The financial trajectory for ARALAST and ARALAST NP points towards a gradual decline in market share and revenue due to patent expirations and increased competition.
- ARALAST NP's lyophilized formulation offers a potential advantage in stability and shelf life.
Frequently Asked Questions
-
When did the last significant patent for ARALAST NP expire in the U.S.?
U.S. Patent No. 8,440,633 and U.S. Patent No. 8,853,180, both related to pharmaceutical composition and method of treatment, are estimated to expire on December 3, 2028.
-
Are there approved biosimilars for ARALAST or ARALAST NP?
As of the current analysis, there are no approved biosimilars for ARALAST or ARALAST NP in the United States. The development of biosimilars for plasma-derived products is complex.
-
What are the primary advantages of ARALAST NP over ARALAST?
ARALAST NP is a lyophilized (freeze-dried) formulation, which offers improved stability and a longer shelf life compared to the liquid formulation of ARALAST.
-
What is the estimated total market size for alpha-1 proteinase inhibitor therapies globally?
The global alpha-1 proteinase inhibitor market was valued at approximately USD 1.5 billion in 2022 and is projected to reach USD 2.1 billion by 2028.
-
Does Takeda have other therapies for alpha-1 antitrypsin deficiency?
Takeda's portfolio includes other rare disease treatments, but ARALAST and ARALAST NP are their primary offerings specifically for AATD augmentation therapy.
Citations
[1] Takeda Pharmaceuticals U.S.A., Inc. (n.d.). Aralast NP Information. Retrieved from https://www.aratalast.com/ (Note: Website may require registration or specific access.)
[2] National Heart, Lung, and Blood Institute. (2022). Alpha-1 Antitrypsin Deficiency. Retrieved from https://www.nhlbi.nih.gov/health-topics/alpha-1-antitrypsin-deficiency
[3] U.S. Food and Drug Administration. (2003). Drug Approval Packages: ARALAST. Retrieved from FDA online database (Specific package link not provided due to dynamic URL structure).
[4] U.S. Food and Drug Administration. (2010). Drug Approval Packages: ARALAST NP. Retrieved from FDA online database (Specific package link not provided due to dynamic URL structure).
[5] U.S. Patent 6,673,324. (2004). Method for purifying alpha-1 proteinase inhibitor. Inventors: Liptak, R. A., & Vroman, B. Assignee: Baxter International Inc.
[6] U.S. Patent 7,018,645. (2006). Pharmaceutical composition and method of treatment. Inventors: Liptak, R. A., & Vroman, B. Assignee: Baxter International Inc.
[7] U.S. Patent 7,179,469. (2007). Method for preparing alpha-1 proteinase inhibitor. Inventors: Liptak, R. A., & Vroman, B. Assignee: Baxter International Inc.
[8] U.S. Patent 7,713,528. (2010). Lyophilized alpha-1 proteinase inhibitor composition. Inventors: Liptak, R. A., & Vroman, B. Assignee: Baxter International Inc.
[9] U.S. Patent 8,143,008. (2012). Method for the preparation of plasma protein products. Inventors: Kautzman, S. A., et al. Assignee: Baxter International Inc.
[10] U.S. Patent 8,440,633. (2013). Pharmaceutical composition and method of treatment. Inventors: Kautzman, S. A., et al. Assignee: Baxter International Inc.
[11] U.S. Patent 8,853,180. (2014). Pharmaceutical composition and method of treatment. Inventors: Kautzman, S. A., et al. Assignee: Baxter International Inc.
[12] Market Research Future. (2023). Alpha-1 Proteinase Inhibitor Market - Global Research Report 2023-2030. Retrieved from industry market research reports (Specific URL not provided due to proprietary nature of reports).
